PURPOSE: To compare the risk of hospitalization between patients with early-stage breast cancer who received different chemotherapy regimens. PATIENT AND METHODS: We identified 3,567 patients older than age 65 years from the SEER/Texas Cancer Registry-Medicare database and 9,327 patients younger than age 65 years from the MarketScan database who were diagnosed with early-stage breast cancer between 2003 and 2007. The selection was nonrandomized and nonprospectively collected. We categorized patients according to the regimens they received: docetaxel (T) and cyclophosphamide (C), doxorubicin (A) and C, TAC, AC + T, dose-dense AC + paclitaxel (P) or AC + weekly P. We compared the rates of chemotherapy-related hospitalizations that occurred within 6 months of chemotherapy initiation and used multivariable logistic regression analysis to identify the factors associated with these hospitalizations. RESULTS: Among patients younger than age 65 years, the hospitalization rates ranged from 6.2% (dose-dense AC + P) to 10.0% (TAC), and those who received TAC and AC + T had significantly higher rates of hospitalization than did patients who received TC. Among patients older than age 65 years, these rates ranged from 12.7% (TC) to 24.2% (TAC) and the rates of hospitalization of patients who received TAC, AC + T, AC, or AC + weekly P were higher than those of patients who received TC. CONCLUSION: TAC and AC + T were associated with the highest risk of hospitalization in patients younger than age 65 years. Among patients older than age 65 years, all regimens (aside from dose-dense AC + P) were associated with a higher risk of hospitalization than TC. Results may be affected by selection biases where less aggressive regimens are offered to frailer patients.
PURPOSE: To compare the risk of hospitalization between patients with early-stage breast cancer who received different chemotherapy regimens. PATIENT AND METHODS: We identified 3,567 patients older than age 65 years from the SEER/Texas Cancer Registry-Medicare database and 9,327 patients younger than age 65 years from the MarketScan database who were diagnosed with early-stage breast cancer between 2003 and 2007. The selection was nonrandomized and nonprospectively collected. We categorized patients according to the regimens they received: docetaxel (T) and cyclophosphamide (C), doxorubicin (A) and C, TAC, AC + T, dose-dense AC + paclitaxel (P) or AC + weekly P. We compared the rates of chemotherapy-related hospitalizations that occurred within 6 months of chemotherapy initiation and used multivariable logistic regression analysis to identify the factors associated with these hospitalizations. RESULTS: Among patients younger than age 65 years, the hospitalization rates ranged from 6.2% (dose-dense AC + P) to 10.0% (TAC), and those who received TAC and AC + T had significantly higher rates of hospitalization than did patients who received TC. Among patients older than age 65 years, these rates ranged from 12.7% (TC) to 24.2% (TAC) and the rates of hospitalization of patients who received TAC, AC + T, AC, or AC + weekly P were higher than those of patients who received TC. CONCLUSION: TAC and AC + T were associated with the highest risk of hospitalization in patients younger than age 65 years. Among patients older than age 65 years, all regimens (aside from dose-dense AC + P) were associated with a higher risk of hospitalization than TC. Results may be affected by selection biases where less aggressive regimens are offered to frailer patients.
Authors: Sharon H Giordano; Yu-Li Lin; Yong Fang Kuo; Gabriel N Hortobagyi; James S Goodwin Journal: J Clin Oncol Date: 2012-05-21 Impact factor: 44.544
Authors: B Fisher; S Anderson; E Tan-Chiu; N Wolmark; D L Wickerham; E R Fisher; N V Dimitrov; J N Atkins; N Abramson; S Merajver; E H Romond; C G Kardinal; H R Shibata; R G Margolese; W B Farrar Journal: J Clin Oncol Date: 2001-02-15 Impact factor: 44.544
Authors: Marc L Citron; Donald A Berry; Constance Cirrincione; Clifford Hudis; Eric P Winer; William J Gradishar; Nancy E Davidson; Silvana Martino; Robert Livingston; James N Ingle; Edith A Perez; John Carpenter; David Hurd; James F Holland; Barbara L Smith; Carolyn I Sartor; Eleanor H Leung; Jeffrey Abrams; Richard L Schilsky; Hyman B Muss; Larry Norton Journal: J Clin Oncol Date: 2003-02-13 Impact factor: 44.544
Authors: Joan L Warren; Linda C Harlan; Angela Fahey; Beth A Virnig; Jean L Freeman; Carrie N Klabunde; Gregory S Cooper; Kevin B Knopf Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Shlomit Strulov Shachar; Allison M Deal; Marc Weinberg; Grant R Williams; Kirsten A Nyrop; Karteek Popuri; Seul Ki Choi; Hyman B Muss Journal: Clin Cancer Res Date: 2017-01-31 Impact factor: 12.531
Authors: Kirsten A Nyrop; Allison M Deal; Shlomit S Shachar; Ethan Basch; Bryce B Reeve; Seul Ki Choi; Jordan T Lee; William A Wood; Carey K Anders; Lisa A Carey; Elizabeth C Dees; Trevor A Jolly; Katherine E Reeder-Hayes; Gretchen G Kimmick; Meghan S Karuturi; Raquel E Reinbolt; JoEllen C Speca; Hyman B Muss Journal: Oncologist Date: 2018-12-14
Authors: Aron S Rosenstock; Jiangong Niu; Sharon H Giordano; Hui Zhao; Antonio C Wolff; Mariana Chavez-MacGregor Journal: Cancer Date: 2017-12-13 Impact factor: 6.860
Authors: Courtney P Williams; Kelly M Kenzik; Andres Azuero; Grant R Williams; Maria Pisu; Karina I Halilova; Stacey A Ingram; Supriya K Yagnik; Andres Forero; Smita Bhatia; Gabrielle B Rocque Journal: Oncologist Date: 2018-08-17
Authors: Kenneth L Kehl; Chan Shen; Jennifer K Litton; Banu Arun; Sharon H Giordano Journal: Breast Cancer Res Treat Date: 2015-12-26 Impact factor: 4.872
Authors: Alexis D Leal; Holly Van Houten; Lindsey Sangaralingham; Rachel A Freedman; Ahmedin Jemal; Heather B Neuman; Tufia C Haddad; Robert W Mutter; Theresa H M Keegan; Sarah S Mougalian; Charles L Loprinzi; Cary P Gross; Nilay Shah; Kathryn J Ruddy Journal: Clin Breast Cancer Date: 2017-09-22 Impact factor: 3.225